Treatment of metastatic TNBC patients remains challenging despite recent incorporation of immune checkpoint inhibitors and antibody–drug conjugates targeting trop-2 (sacituzumab govitecan) or HER-2 (trastuzumab deruxtecan), largely due to tumor heterogeneity and acquired chemotherapy resistance [39,40]. Here, TACSTD2 is linked to neoplasm.